Novel imaging biomarkers for preclinical osteoarthritis drug development

Bidragets beskrivning

Osteoarthritis is the most common joint disease in the world and there is currently no cure available for it. The majority of developed drugs have shown no improvement in patient conditions in clinical trials. The lack of sensitive biomarkers has been proposed as one of the reasons hindering the development of osteoarthritis therapeutics. In this project, we will develop imaging biomarkers reflecting both structural and symptom modifications. Developed biomarkers will be used in preclinical efficacy studies for novel osteoarthritis treatment strategies that target oxygen-sensing in joints.
Visa mer

Startår

2022

Slutår

2027

Beviljade finansiering

Mikko Finnilä Orcid -palvelun logo
447 650 €

Andra beslut

372117
Akademiforskarens forskningskostnader(2025)
199 989 €
353755
Akademiforskarens forskningskostnader(2022)
300 000 €

Finansiär

Finlands Akademi

Typ av finansiering

Akademiforskare

Övriga uppgifter

Finansieringsbeslutets nummer

347445

Vetenskapsområden

Medicinsk teknik

Forskningsområden

Lääketieteellinen tekniikka

Identifierade teman

musculoskeletal diseases